<DOC>
	<DOCNO>NCT01871480</DOCNO>
	<brief_summary>Lung cancer common cancer worldwide , non-small cell lung cancer ( NSCLC ) comprise 85 % lung cancer case , lead cause cancer mortality , adenocarcinoma prevalent subtype . Gefitinib show low efficiency treatment second third-line patient advance adenocarcinoma NSCLC . It necessary improve efficiency treatment patient advance NSCLC . Immunotherapy cytokine-induced killer cell ( CIK ) may improve tumor control survival , well good quality life . This study evaluate efficacy Autologous CIK Transfusion plus Gefitinib advance , recurrence , metastatic adenocarcinoma NSCLC .</brief_summary>
	<brief_title>CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment Advanced Adenocarcinoma Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Lung cancer common cancer worldwide , non-small cell lung cancer ( NSCLC ) comprise 85 % lung cancer case , lead cause cancer mortality , adenocarcinoma prevalent subtype . The epidermal growth factor receptor ( EGFR ) adenosine triphosphate-competitive tyrosine kinase inhibitor gefitinib show success treatment advance adenocarcinoma NSCLC follow failure front-line chemotherapy . However , efficiency treatment second third-line patient advance adenocarcinoma NSCLC also low . It necessary improve efficiency treatment patient advance NSCLC . Biological treatment effective adjuvant treatment comprehensive cancer treatment . Immunotherapy cytokine-induced killer cell ( CIK ) characterize fast amplification , strong anti-cancer activity broad anti-tumor spectrum , effect may improve tumor control survival , well good quality life . This study evaluate efficacy Autologous CIK Transfusion plus Gefitinib advance , recurrence , metastatic adenocarcinoma NSCLC .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Age 18 80 year Histologically cytologically proven advanced adenocarcinoma nonsmallcell lung cancer Life expectancy 12 week Not receive EGFR agent cell immunotherapy entry study World Health Organization Eastern Cooperative Oncology Group Performance Status 03 Gefitinib second third line therapy More 4 week must completion last dose chemotherapy , radiation therapy , investigational therapy patient must adequately recover effect Disease measurable Patients must adequate organ marrow function define : white blood cell : 3.0×109/L , Neutrophils : 1.5×109/L , Platelets : 75×109/L , Hemoglobin 80g/L , Serum total bilirubin le 1.25 fold upper normal limit ( ULN ) , Serum glutamicoxal ( ) acetic transaminase : le 2.5×ULN , Serum glutamate pyruvate transaminase : le 2.5×ULN , Serum creatinine : le 1.25×ULN , Blood urea nitrogen : le 2×ULN . Pregnancy test : test woman childbearing period must negative entry study Subject must good compliance voluntarily sign write informed consent Acute infection Uncontrolled concurrent illness : hypersensitiveness , asthma , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , serious heart valve disease Psychiatric illness , pharmacological dependence , situation would limit compliance study requirement History neoplasms Coagulation disorder bleeding tendency Pertinacious hypertension（systolic blood pressure &gt; 140 mmHg diastolic blood pressure &gt; 90 mmHg ) aggressive therapy Brain metastasis symptomatic Severe liver dysfunction Autoimmune disease ( e.g . systemic lupus erythematosus , rheumatoid arthritis , thyroadenitis , et al ) Patients diagnose virus hepatitis , syphilis HIV , infectious disease Employment corticosteroid immunodepressive hormone therapy With main organ transplantation Pregnant lactate woman Known suspect patient severe hypersensitivity CIK gefitinib component gefitinib Patients receive investigational agent 30 day prepare participate investigation clinical period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>CIK</keyword>
	<keyword>Gefitinib</keyword>
	<keyword>Adenocarcinoma</keyword>
</DOC>